Clinical trials: Depression / Major Depressive Disorder
Depression
Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
The primary study comparing effectiveness for suicidal ideation and/or behavior of two antidepressant medications in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts has been…
- Trial name
- NCT00429169
- Testing
- Paroxetine, Bupropion
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
- Trial name
- NCT01432457
- Testing
- desvenlafaxine succinate sustained-release 50 mg/day, desvenlafaxine succinate sustained-release 100 mg/day
- Where
- 61 sites in United States
- Volunteers
- 924 people
- Sponsor
- Pfizer
Major Depressive Disorder
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous…
- Trial name
- NCT01667926
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Major Depression, End Stage Renal Disease
Bupropion for Depression in ESRD Patients on Hemodialysis
The proposed study will evaluate the response and remission rates for major depressive disorder (MDD) in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD) treated with bupropion or fluoxetine for 12…
- Trial name
- NCT02238977
- Testing
- Fluoxetine, Bupropion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Major Depressive Disorder, Depression
Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)
The objective of this clinical trial is to evaluate whether an anti-inflammatory medication, pentoxifylline, reduces depressive symptoms and improves artery function.
- Conditions
- Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD)
- Trial name
- INFLAMED (NCT01625845)
- Testing
- Pentoxifylline, Standard Treatment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Major Depressive Disorder
ANC-501 in the Treatment of Adults With Major Depressive Disorder
A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
- Trial name
- NCT05439603
- Testing
- ANC-501
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Hepatitis C, Chronic
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
The purpose of this study is to determine whether the use of an antidepressant (escitalopram) can prevent depressive episodes that appear during the treatment with peg-interferon and ribavirin in patients with chronic hepatitis C.
- Trial name
- NCT00166296
- Testing
- Escitalopram
- Where
- 15 sites in Spain
- Volunteers
- 133 people
- Sponsor
- Germans Trias i Pujol Hospital
Major Depressive Disorder
The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD
Objectives: 1. To evaluate the relationship between improvement of Hamilton Depression Rating Scale (HAMD) score and basal SERT availability (binding potential) for the prognosis of MDD subjects being treated with Sertraline HCl…
- Trial name
- STAPMDDTDM (NCT02473783)
- Testing
- Sertraline HCl, I-123-ADAM SPECT
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tri-Service General Hospital (TSGH)
Major Depressive Disorder
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood.
- Trial name
- NCT01804270
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Paul E. Croarkin
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Anxiety
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a…
- Trial name
- NCT02498392
- Testing
- JNJ-42165279
- Where
- 32 sites in United States, Moldova and 4 more
- Volunteers
- 161 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder
A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs).
- Trial name
- NCT01250873
- Testing
- LY2216684, Sertraline
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Nicotine Dependence
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
The primary purpose of this study is to determine whether, among smokers with elevated depressive symptoms, sequential antidepressant pharmacotherapy with fluoxetine (20 mg) begun 8 weeks prior to and extended throughout standard…
- Conditions
- Major Depressive Disorder, Nicotine Dependence, Depression
- Trial name
- NCT00578669
- Testing
- Fluoxetine, Dextrose
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Butler Hospital